Stivarga Real Life Evidence in Hungary

The study aims to evaluate use of regorafenib in clinical practice in Hungary. The study should provide information about clinical characteristics of Hungarian regorafenib patients as well as information about safety and efficacy of regorafenib in Hungarian patients with metastatic colorectal cancer. This much needed data is required by the National Health Insurance Fund in order to accept regorafenib into the regular reimbursement system. This study is proposed to be based on patient data from the Hungarian National Health Insurance Fund’s Database. Data to be analyzed includes patient demography and baseline tumor characteristics, overall survival, time to treatment failure, duration of treatment, average dose and dose modifications, and adverse events. Further, treatment costs will be estimated.本研究旨在评估瑞戈非尼（regorafenib）在匈牙利临床实践中的应用情况。本研究将提供匈牙利瑞戈非尼用药患者的临床特征数据，以及匈牙利转移性结直肠癌患者使用瑞戈非尼的安全性与疗效相关信息。此项亟需的数据是匈牙利国家医疗保险基金为将瑞戈非尼纳入常规报销体系所必需的资料。本研究拟基于匈牙利国家医疗保险基金数据库中的患者数据开展。待分析的数据涵盖患者人口统计学特征、基线肿瘤特征、总生存期、治疗失败时间、治疗持续时间、平均给药剂量及剂量调整情况，以及不良事件。此外，本研究还将对治疗成本进行估算。